Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free XBIO Stock Alerts

Xenetic Biosciences (XBIO) Financials

Xenetic Biosciences logo
$4.63 +0.38 (+8.94%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$4.37 -0.26 (-5.62%)
As of 08:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Xenetic Biosciences

Annual Income Statements for Xenetic Biosciences

This table shows Xenetic Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -58 -3.60 -7.30 -18 -11 -5.65 -6.55 -4.13 -3.96 -2.68
Consolidated Net Income / (Loss)		 -13 -54 -3.60 -7.30 -13 -11 -5.65 -6.55 -4.13 -3.96 -2.68
Net Income / (Loss) Continuing Operations		 -13 -54 -3.60 -7.30 -13 -11 -5.65 -6.55 -4.13 -3.96 -2.68
Total Pre-Tax Income 		-13 -54 -3.60 -7.30 -13 -14 -5.65 -6.55 -4.13 -3.96 -2.68
Total Operating Income		 -9.82 -47 -3.57 -7.28 -13 -14 -5.75 -6.72 -4.52 -4.20 -2.83
Total Gross Profit		 0.00 3.00 7.59 0.00 0.03 0.44 1.16 1.71 2.54 2.50 2.98
Total Revenue		 0.00 3.00 7.59 0.00 0.03 0.44 1.16 1.71 2.54 2.50 2.98
Operating Revenue		 0.00 3.00 7.59 0.00 0.03 0.44 1.16 1.71 2.54 2.50 2.98
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.82 50 11 7.28 13 14 6.91 8.42 7.06 6.70 5.81
Selling, General & Admin Expense		 6.39 6.69 6.94 4.39 4.73 3.40 3.74 3.65 3.56 3.42 2.75
Research & Development Expense		 3.43 44 4.22 2.88 4.89 1.73 3.16 4.77 3.49 3.29 3.07
Total Other Income / (Expense), net		 -2.69 -6.78 -0.03 -0.02 0.11 0.13 0.10 0.17 0.38 0.24 0.15
Interest Expense		 0.27 7.12 0.00 -0.00 -0.11 -0.13 -0.10 -0.17 -0.36 -0.25 -0.15
Other Income / (Expense), net		 -2.42 0.35 -0.02 -0.02 0.00 -0.00 0.00 -0.00 0.03 -0.01 0.01
Basic Earnings per Share		 ($2.96) ($7.84) ($0.41) ($9.66) ($6.33) ($1.70) - - ($2.71) ($2.57) ($1.58)
Weighted Average Basic Shares Outstanding		 4.22M 7.43M 8.67M 756.02K 2.85M 6.39M 10.28M 15.17M 1.53M 1.54M 1.70M
Diluted Earnings per Share		 ($2.96) ($7.84) ($0.41) ($9.66) ($6.33) ($1.70) - - ($2.71) ($2.57) ($1.58)
Weighted Average Diluted Shares Outstanding		 4.22M 7.43M 8.67M 756.02K 2.85M 6.39M 10.28M 15.17M 1.53M 1.54M 1.70M
Weighted Average Basic & Diluted Shares Outstanding		 4.22M 7.43M 8.67M 756.02K 2.85M 6.39M 10.28M 15.17M 1.54M 1.54M 2.29M

Quarterly Income Statements for Xenetic Biosciences

This table shows Xenetic Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.17 -1.20 -1.27 -0.44 -1.05 -0.90 -0.69 -0.51 -0.58 -0.46 -0.93
Consolidated Net Income / (Loss)		 -1.17 -1.20 -1.27 -0.44 -1.05 -0.90 -0.69 -0.51 -0.58 -0.46 -0.93
Net Income / (Loss) Continuing Operations		 -1.17 -1.20 -1.27 -0.44 -1.05 -0.90 -0.69 -0.51 -0.58 -0.46 -0.93
Total Pre-Tax Income 		-1.17 -1.20 -1.27 -0.44 -1.05 -0.90 -0.69 -0.51 -0.58 -0.46 -0.93
Total Operating Income		 -1.26 -1.27 -1.34 -0.50 -1.10 -0.94 -0.72 -0.54 -0.62 -0.50 -0.97
Total Gross Profit		 0.67 0.51 0.73 0.61 0.65 0.59 0.59 1.03 0.77 0.81 0.66
Total Revenue		 0.67 0.51 0.73 0.61 0.65 0.59 0.59 1.03 0.77 0.81 0.66
Operating Revenue		 0.67 0.51 0.73 0.61 0.65 0.59 0.59 1.03 0.77 0.81 0.66
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 1.93 1.78 2.06 1.11 1.75 1.54 1.31 1.57 1.39 1.31 1.63
Selling, General & Admin Expense		 0.95 0.83 1.13 0.75 0.71 0.66 0.66 0.82 0.62 0.65 1.08
Research & Development Expense		 0.98 0.94 0.93 0.37 1.04 0.88 0.66 0.76 0.77 0.66 0.55
Total Other Income / (Expense), net		 0.08 0.07 0.06 0.06 0.04 0.04 0.04 0.03 0.04 0.05 0.04
Interest & Investment Income		 - - - - - 0.04 0.03 - - 0.05 0.04
Other Income / (Expense), net		 0.00 0.00 -0.00 0.00 -0.01 0.00 0.00 0.00 0.00 -0.00 -0.00
Basic Earnings per Share		 ($0.77) ($0.78) ($0.83) ($0.28) ($0.68) - ($0.45) ($0.33) ($0.21) - ($0.41)
Weighted Average Basic Shares Outstanding		 1.53M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.70M 2.29M 2.29M
Diluted Earnings per Share		 ($0.77) ($0.78) ($0.83) ($0.28) ($0.68) - ($0.45) ($0.33) ($0.21) - ($0.41)
Weighted Average Diluted Shares Outstanding		 1.53M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.70M 2.29M 2.29M
Weighted Average Basic & Diluted Shares Outstanding		 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 2.29M 2.29M 2.29M 2.34M

Annual Cash Flow Statements for Xenetic Biosciences

This table details how cash moves in and out of Xenetic Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.38 3.92 1.48 -4.96 9.73 1.16 6.72 -5.15 -4.11 -2.82 1.72
Net Cash From Operating Activities		 -5.30 -8.79 1.49 -6.46 -6.40 -4.27 -4.74 -4.65 -4.11 -2.82 -2.29
Net Cash From Continuing Operating Activities		 -5.30 -8.79 1.49 -6.46 -6.45 -4.27 -4.74 -4.65 -4.11 -2.82 -2.29
Net Income / (Loss) Continuing Operations		 -13 -54 -3.60 -7.30 -13 -11 -5.65 -6.55 -4.13 -3.96 -2.68
Consolidated Net Income / (Loss)		 -13 -54 -3.60 -7.30 -13 -11 -5.65 -6.55 -4.13 -3.96 -2.68
Non-Cash Adjustments To Reconcile Net Income		 3.95 51 1.79 1.42 7.25 9.57 0.41 2.31 0.28 0.17 0.06
Changes in Operating Assets and Liabilities, net		 3.09 -6.38 3.27 -0.60 -0.88 -2.97 0.46 -0.43 -0.26 0.97 0.33
Net Cash From Investing Activities		 0.01 -0.02 -0.01 0.02 0.00 0.00 0.00 -0.50 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.01 -0.02 -0.01 0.02 0.00 0.00 0.00 -0.50 0.00 0.00 0.00
Net Cash From Financing Activities		 3.00 13 0.00 1.48 16 5.43 11 0.00 0.00 0.00 4.00
Net Cash From Continuing Financing Activities		 3.00 13 0.00 1.48 16 5.43 11 0.00 0.00 0.00 4.00
Issuance of Common Equity		 - - - 0.00 16 5.43 11 - - 0.00 4.00
Cash Interest Paid		 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Xenetic Biosciences

This table details how cash moves in and out of Xenetic Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -0.79 -1.16 -0.53 -0.46 -0.67 -1.00 -0.38 -0.66 3.76 -0.54 -0.88
Net Cash From Operating Activities		 -0.79 -1.16 -0.53 -0.46 -0.67 -1.00 -0.38 -0.66 -0.24 -0.54 -0.88
Net Cash From Continuing Operating Activities		 -0.79 -1.16 -0.53 -0.46 -0.67 -1.00 -0.38 -0.66 -0.24 -0.54 -0.88
Net Income / (Loss) Continuing Operations		 -1.17 -1.20 -1.27 -0.44 -1.05 -0.90 -0.69 -0.51 -0.58 -0.46 -0.93
Consolidated Net Income / (Loss)		 -1.17 -1.20 -1.27 -0.44 -1.05 -0.90 -0.69 -0.51 -0.58 -0.46 -0.93
Non-Cash Adjustments To Reconcile Net Income		 0.07 0.08 0.04 0.03 0.03 0.02 0.02 0.02 0.01 0.01 0.05
Changes in Operating Assets and Liabilities, net		 0.30 -0.04 0.71 -0.05 0.36 -0.12 0.29 -0.16 0.32 -0.09 0.00

Annual Balance Sheets for Xenetic Biosciences

This table presents Xenetic Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 17 21 19 14 22 13 20 15 11 6.90 8.36
Total Current Assets		 4.19 8.34 5.88 1.19 11 12 19 14 9.59 6.59 8.05
Cash & Equivalents		 0.13 4.05 5.53 0.57 10 12 18 13 8.98 6.17 7.88
Prepaid Expenses		 0.25 1.22 0.29 0.56 0.72 0.84 0.48 0.56 0.60 0.42 0.17
Plant, Property, & Equipment, net		 0.06 0.04 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 13 13 13 13 10 0.81 1.09 1.07 1.02 0.31 0.31
Other Noncurrent Operating Assets		 0.13 0.07 0.72 0.71 1.21 0.81 1.09 1.07 1.02 0.31 0.31
Total Liabilities & Shareholders' Equity		 17 21 19 14 22 13 20 15 11 6.90 8.36
Total Liabilities		 10 4.80 4.86 4.52 4.33 0.96 1.42 1.07 0.81 0.89 0.97
Total Current Liabilities		 7.34 1.87 1.94 1.60 1.42 0.94 1.42 1.07 0.81 0.89 0.97
Accounts Payable		 2.18 1.01 0.79 1.60 1.42 0.94 1.42 1.07 0.81 0.89 0.97
Total Noncurrent Liabilities		 2.96 2.94 2.92 2.92 2.92 0.03 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.61 16 14 9.91 17 12 18 14 9.80 6.01 7.40
Total Preferred & Common Equity		 6.61 16 14 9.91 17 12 18 14 9.80 6.01 7.40
Preferred Stock		 - - 0.00 - 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Common Equity		 6.61 16 14 9.91 17 12 18 14 9.79 6.01 7.39
Common Stock		 100 164 165 168 188 194 206 208 208 208 212
Retained Earnings		 -88 -142 -146 -153 -166 -177 -183 -189 -193 -197 -200
Treasury Stock		 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28
Accumulated Other Comprehensive Income / (Loss)		 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25

Quarterly Balance Sheets for Xenetic Biosciences

This table presents Xenetic Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 12 9.39 9.03 8.05 5.79 5.35 5.07 7.91 6.97
Total Current Assets		 11 8.38 8.01 7.03 5.48 5.35 5.07 7.60 6.65
Cash & Equivalents		 9.78 7.82 7.30 6.84 5.16 4.78 4.12 7.35 6.47
Prepaid Expenses		 1.48 0.55 0.72 0.19 0.31 0.57 0.95 0.25 0.18
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.70 1.02 1.02 1.02 0.31 0.00 0.00 0.31 0.31
Other Noncurrent Operating Assets		 0.70 1.02 1.02 1.02 0.31 0.00 0.00 0.31 0.31
Total Liabilities & Shareholders' Equity		 12 9.39 9.03 8.05 5.79 5.35 5.07 7.91 6.97
Total Liabilities		 1.07 0.72 1.59 1.01 0.67 0.90 1.11 0.96 0.89
Total Current Liabilities		 1.07 0.72 1.59 1.01 0.67 0.90 1.11 0.96 0.89
Accounts Payable		 1.07 0.72 1.59 1.01 0.67 0.90 1.11 0.96 0.89
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 11 8.68 7.45 7.04 5.12 4.45 3.96 6.95 6.07
Total Preferred & Common Equity		 11 8.68 7.45 7.04 5.12 4.45 3.96 6.95 6.07
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 11 8.68 7.44 7.03 5.12 4.45 3.95 6.95 6.07
Common Stock		 208 208 208 208 208 208 208 212 212
Retained Earnings		 -192 -194 -196 -196 -198 -199 -199 -200 -201
Treasury Stock		 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28 -5.28
Accumulated Other Comprehensive Income / (Loss)		 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25

Annual Metrics And Ratios for Xenetic Biosciences

This table displays calculated financial ratios and metrics derived from Xenetic Biosciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 150,513,011.00 8,288,644.00 8,717,541.00 9,403,889.00 5,755,141.00 6,296,227.00 13,387,978.00 15,166,596.00 1,540,684.00 1,542,139.00 2,291,056.00
DEI Adjusted Shares Outstanding		 1,254,275.00 69,072.00 72,646.00 78,366.00 575,514.00 629,623.00 1,338,798.00 1,516,660.00 1,540,684.00 1,542,139.00 2,291,056.00
DEI Earnings Per Adjusted Shares Outstanding		 -9.97 -843.20 -49.49 -93.16 -31.38 -17.30 -4.22 -4.32 -2.68 -2.57 -1.17
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 152.83% -100.00% 0.00% 1,180.15% 165.64% 47.06% 48.80% -1.56% 19.04%
EBITDA Growth		 15.14% -285.02% 92.32% -104.09% -76.79% -8.00% 58.95% -17.20% 32.90% 6.24% 32.81%
EBIT Growth		 14.52% -284.59% 92.37% -103.18% -76.46% -8.19% 58.78% -16.95% 33.17% 6.24% 32.81%
NOPAT Growth		 24.01% -382.90% 92.48% -103.89% -77.11% -8.15% 58.77% -16.90% 32.78% 6.89% 32.58%
Net Income Growth		 12.58% -333.39% 93.37% -103.07% -74.99% 14.73% 48.18% -16.07% 36.90% 4.22% 32.31%
EPS Growth		 -2,590.91% -164.86% 94.77% -103.07% 34.47% 73.14% 0.00% 0.00% 0.00% 5.17% 38.52%
Operating Cash Flow Growth		 58.21% -65.77% 117.00% -532.60% 1.00% 33.32% -11.03% 1.93% 11.46% 31.52% 18.84%
Free Cash Flow Firm Growth		 41.81% -622.32% 102.20% -762.86% -16.33% 45.40% 3.17% -46.40% 32.90% 42.40% 16.09%
Invested Capital Growth		 -18.94% 88.07% -27.81% 6.58% -26.19% -89.95% -78.16% 266.03% 47.78% -119.49% -207.98%
Revenue Q/Q Growth		 0.00% 0.00% 145.87% -100.00% 0.00% 36.65% 18.51% 9.94% 7.86% -0.92% 4.11%
EBITDA Q/Q Growth		 6.61% 6.65% 56.28% -512.82% 2.93% 0.25% -12.06% 4.28% 6.40% 3.42% 14.60%
EBIT Q/Q Growth		 6.26% 6.64% 56.14% -505.49% 3.07% 0.08% -12.76% 4.39% 6.40% 3.42% 14.60%
NOPAT Q/Q Growth		 13.44% 5.25% 55.74% -503.34% 3.04% 0.11% -12.84% 4.42% 6.38% 3.59% 14.38%
Net Income Q/Q Growth		 5.12% 5.63% 57.36% -500.41% 3.54% -0.27% -12.82% 5.20% 7.00% 2.87% 15.06%
EPS Q/Q Growth		 0.00% -22.69% 71.33% -500.41% -31.88% 50.15% 0.00% 0.00% 6.55% 2.65% 22.93%
Operating Cash Flow Q/Q Growth		 22.61% -66.46% 118.75% -1,005.39% -11.05% 14.51% -11.93% 13.22% -1.03% 4.05% 15.87%
Free Cash Flow Firm Q/Q Growth		 -99.21% -5.43% 109.75% -239.89% -11.67% 18.31% -9.85% 0.60% 10.34% 7.55% 15.36%
Invested Capital Q/Q Growth		 65.59% 112.40% -1.04% -3.55% 10.14% -19.40% -67.43% -18.43% -27.22% -180.39% -194.90%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -1,550.02% -47.06% 0.00% -37,733.84% -3,183.33% -491.96% -392.08% -176.79% -168.39% -95.04%
Operating Margin		 0.00% -1,581.02% -47.05% 0.00% -37,755.86% -3,189.82% -495.12% -393.57% -177.79% -168.16% -95.23%
EBIT Margin		 0.00% -1,569.39% -47.37% 0.00% -37,746.14% -3,189.93% -495.02% -393.66% -176.79% -168.39% -95.04%
Profit (Net Income) Margin		 0.00% -1,806.87% -47.40% 0.00% -37,428.29% -2,493.11% -486.36% -383.87% -162.78% -158.39% -90.07%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 78.87% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 102.17% 115.13% 100.05% 99.99% 99.16% 99.09% 98.25% 97.51% 92.08% 94.07% 94.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -359.62% -24.07% 0.00% -111.92% -259.02% -959.85% -1,343.40% -464.01% -899.75% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 614.31% -1.49% 0.00% -43.70% -248.63% -948.95% -1,331.59% -455.19% -886.32% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -116.33% 0.47% 0.00% 17.73% 184.99% 922.97% 1,302.50% 428.74% 849.62% 0.00%
Return on Equity (ROE)		 -146.38% -475.95% -23.60% -60.30% -94.19% -74.03% -36.88% -40.90% -35.27% -50.12% -40.00%
Cash Return on Invested Capital (CROIC)		 -75.13% -420.76% 8.24% -63.04% -81.78% -95.55% -831.54% -1,457.57% -502.58% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -248.57% -17.91% 0.00% -71.62% -80.27% -34.83% -38.91% -35.46% -48.10% -37.06%
Return on Assets (ROA)		 0.00% -286.18% -17.91% 0.00% -71.02% -62.74% -34.22% -37.95% -32.65% -45.24% -35.12%
Return on Common Equity (ROCE)		 -146.38% -475.88% -23.59% -60.28% -94.17% -74.02% -36.88% -40.89% -35.27% -50.11% -39.99%
Return on Equity Simple (ROE_SIMPLE)		 -189.26% -335.24% -25.14% -73.65% -74.22% -89.18% -30.69% -48.01% -42.21% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.88 -33 -2.50 -5.09 -9.02 -9.76 -4.02 -4.70 -3.16 -2.94 -1.98
NOPAT Margin		 0.00% -1,106.71% -32.94% 0.00% -26,429.10% -2,232.87% -346.58% -275.50% -124.45% -117.71% -66.66%
Net Nonoperating Expense Percent (NNEP)		 -406.33% -973.93% -22.59% -70.76% -68.22% -10.39% -10.90% -11.80% -8.82% -13.43% -9.92%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -32.27% -48.99% -26.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 223.09% 91.47% 0.00% 13,861.41% 778.15% 322.56% 214.07% 140.20% 136.64% 92.24%
R&D to Revenue		 0.00% 1,457.93% 55.59% 0.00% 14,324.80% 396.26% 272.55% 279.50% 137.59% 131.52% 102.99%
Operating Expenses to Revenue		 0.00% 1,681.02% 147.05% 0.00% 37,805.86% 3,289.82% 595.12% 493.57% 277.79% 268.16% 195.23%
Earnings before Interest and Taxes (EBIT)		 -12 -47 -3.59 -7.30 -13 -14 -5.75 -6.72 -4.49 -4.21 -2.83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -47 -3.57 -7.29 -13 -14 -5.71 -6.69 -4.49 -4.21 -2.83
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 22.55 2.20 1.17 1.56 0.48 1.05 0.94 0.32 0.54 1.02 0.67
Price to Tangible Book Value (P/TBV)		 0.00 9.79 9.44 0.00 1.04 1.05 0.94 0.32 0.54 1.02 0.67
Price to Revenue (P/Rev)		 0.00 11.88 2.21 0.00 242.80 29.40 14.88 2.53 2.09 2.46 1.67
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 23.22 2.62 1.28 1.59 0.00 1.92 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 10.51 1.47 0.00 0.00 3.02 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 7.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 13.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.16 -0.19 -0.32 -0.26 -0.41 -0.74 -0.97 -0.98 -0.94 -0.96 -1.05
Leverage Ratio		 1.94 1.66 1.32 1.39 1.33 1.18 1.08 1.08 1.08 1.11 1.14
Compound Leverage Factor		 1.99 1.91 1.32 1.39 1.32 1.17 1.06 1.05 0.99 1.04 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.02% 0.00% 0.02% 0.02% 0.00% 0.02% 0.02% 0.03% 0.02%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 99.98% 99.98% 99.97% 99.98% 99.98% 99.98% 99.98% 99.98% 99.97% 99.98%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.23 -11.94 -8.57 -14.52 -11.07 -13.21 -5.46 -15.93 -21.73 -36.53 -30.12
Noncontrolling Interest Sharing Ratio		 0.00% 0.01% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.57 4.47 3.03 0.75 7.84 13.20 13.18 12.72 11.84 7.37 8.32
Quick Ratio		 0.02 3.78 2.85 0.36 7.33 12.30 12.84 12.20 11.10 6.89 8.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.38 -39 0.85 -5.67 -6.59 -3.60 -3.48 -5.10 -3.42 -1.97 -1.65
Operating Cash Flow to CapEx		 0.00% -52,326.42% 16,129.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -20.14 -5.45 470.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -19.85 -1.23 821.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -19.83 -1.24 816.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.16 0.38 0.00 0.00 0.03 0.07 0.10 0.20 0.29 0.39
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 57.48 216.06 0.00 11.95 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.41 12 8.70 9.27 6.85 0.69 0.15 0.55 0.81 -0.16 -0.49
Invested Capital Turnover		 0.00 0.32 0.73 0.00 0.00 0.12 2.77 4.88 3.73 7.64 -9.21
Increase / (Decrease) in Invested Capital		 -1.50 5.64 -3.35 0.57 -2.43 -6.16 -0.54 0.40 0.26 -0.97 -0.33
Enterprise Value (EV)		 149 32 11 15 -2.08 1.32 -0.97 -8.77 -3.67 -0.01 -2.91
Market Capitalization		 149 36 17 15 8.29 13 17 4.32 5.32 6.15 4.97
Book Value per Share		 $0.04 $1.95 $1.64 $1.05 $2.99 $1.94 $1.37 $0.90 $6.36 $3.89 $3.23
Tangible Book Value per Share		 ($0.04) $0.44 $0.20 ($0.28) $1.38 $1.94 $1.37 $0.90 $6.36 $3.89 $3.23
Total Capital		 6.61 16 14 9.91 17 12 18 14 9.80 6.01 7.40
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.20 -4.11 -5.60 -0.64 -10 -12 -18 -13 -8.98 -6.17 -7.88
Capital Expenditures (CapEx)		 -0.01 0.02 0.01 -0.02 -0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.35 2.36 -1.66 -1.04 -0.69 -0.09 -0.94 -0.52 -0.21 -0.47 -0.80
Debt-free Net Working Capital (DFNWC)		 -3.15 6.47 3.94 -0.41 9.67 11 17 13 8.78 5.69 7.08
Net Working Capital (NWC)		 -3.15 6.47 3.94 -0.41 9.67 11 17 13 8.78 5.69 7.08
Net Nonoperating Expense (NNE)		 5.63 21 1.10 2.21 3.75 1.14 1.62 1.85 0.97 1.02 0.70
Net Nonoperating Obligations (NNO)		 -0.20 -4.11 -5.60 -0.64 -10 -12 -18 -13 -8.98 -6.17 -7.88
Total Depreciation and Amortization (D&A)		 0.16 0.58 0.02 0.02 0.00 0.03 0.04 0.03 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 78.60% -21.87% 0.00% -2,030.58% -21.74% -81.13% -30.29% -8.10% -18.89% -26.94%
Debt-free Net Working Capital to Revenue		 0.00% 215.76% 51.96% 0.00% 28,345.37% 2,616.50% 1,490.69% 737.01% 345.56% 227.70% 237.93%
Net Working Capital to Revenue		 0.00% 215.76% 51.96% 0.00% 28,345.37% 2,616.50% 1,490.69% 737.01% 345.56% 227.70% 237.93%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($10.80) ($940.80) ($49.20) ($96.00) ($63.30) ($17.00) ($5.50) $0.00 $0.00 ($2.57) ($1.58)
Adjusted Weighted Average Basic Shares Outstanding		 1.27M 72.11K 72.11K 87.03K 628.49K 874.67K 1.34M 1.52M 1.54M 1.54M 1.70M
Adjusted Diluted Earnings per Share		 ($10.80) ($940.80) ($49.20) ($96.00) ($63.30) ($17.00) ($5.50) $0.00 $0.00 ($2.57) ($1.58)
Adjusted Weighted Average Diluted Shares Outstanding		 1.27M 72.11K 72.11K 87.03K 628.49K 874.67K 1.34M 1.52M 1.54M 1.54M 1.70M
Adjusted Basic & Diluted Earnings per Share		 ($10.80) ($940.80) ($49.20) ($96.00) ($63.30) ($17.00) ($5.50) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.17M 61.92K 72.22K 75.59K 285.25K 639.24K 1.03M 1.52M 1.54M 1.54M 2.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.88 -33 -2.50 -5.09 -6.72 -3.29 -4.02 -4.70 -3.16 -2.94 -1.98
Normalized NOPAT Margin		 0.00% -1,106.71% -32.94% 0.00% -19,695.34% -752.08% -346.58% -275.50% -124.45% -117.71% -66.66%
Pre Tax Income Margin		 0.00% -1,806.87% -47.40% 0.00% -37,428.29% -3,161.06% -486.36% -383.87% -162.78% -158.39% -90.07%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -45.85 -6.61 -1,976.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -25.75 -4.66 -1,374.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -45.83 -6.61 -1,981.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -25.73 -4.66 -1,379.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Xenetic Biosciences

This table displays calculated financial ratios and metrics derived from Xenetic Biosciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 1,540,684.00 1,540,684.00 1,540,684.00 1,542,139.00 1,542,139.00 1,542,139.00 1,542,139.00 1,542,139.00 2,291,056.00 2,291,056.00 2,291,056.00
DEI Adjusted Shares Outstanding		 1,540,684.00 1,540,684.00 1,540,684.00 1,542,139.00 1,542,139.00 1,542,139.00 1,542,139.00 1,542,139.00 2,291,056.00 2,291,056.00 2,291,056.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.76 -0.78 -0.83 -0.28 -0.68 -0.59 -0.45 -0.33 -0.25 -0.20 -0.41
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 37.99% -15.69% 11.58% 0.50% -3.44% 16.14% -18.79% 67.19% 18.11% 36.01% 11.99%
EBITDA Growth		 19.66% -39.28% -13.62% 56.60% 11.86% 25.70% 45.95% -8.59% 43.70% 46.71% -34.42%
EBIT Growth		 19.66% -39.28% -13.62% 56.60% 11.86% 25.70% 45.95% -8.59% 43.70% 46.71% -34.42%
NOPAT Growth		 19.68% -38.60% -11.62% 56.44% 12.47% 25.70% 45.83% -9.06% 43.32% 46.72% -34.14%
Net Income Growth		 20.98% -39.53% -21.22% 58.63% 9.99% 24.43% 45.94% -16.78% 45.09% 49.47% -34.99%
EPS Growth		 -670.00% 0.00% 0.00% 59.42% 11.69% 0.00% 45.78% -17.86% 69.12% 0.00% 8.89%
Operating Cash Flow Growth		 -5.61% -5.16% 58.62% 51.66% 15.01% 13.58% 26.90% -43.40% 63.99% 46.46% -128.09%
Free Cash Flow Firm Growth		 23.58% -18.33% 103.98% 145.77% 117.66% 126.74% -144.13% -103.31% -152.93% -98.02% -1,911.15%
Invested Capital Growth		 47.78% -1.24% -87.23% -82.35% -119.49% -104.73% -324.00% -183.95% -207.98% -881.78% -20.99%
Revenue Q/Q Growth		 9.95% -23.98% 42.20% -15.44% 5.63% -8.56% -0.57% 74.09% -25.38% 5.30% -18.13%
EBITDA Q/Q Growth		 -9.41% -1.04% -5.44% 62.77% -122.18% 14.83% 23.28% 25.20% -15.19% 19.38% -93.52%
EBIT Q/Q Growth		 -9.41% -1.04% -5.44% 62.77% -122.18% 14.83% 23.28% 25.20% -15.19% 19.38% -93.52%
NOPAT Q/Q Growth		 -9.50% -1.02% -5.44% 62.65% -120.06% 14.26% 23.13% 24.80% -14.37% 19.41% -93.52%
Net Income Q/Q Growth		 -10.98% -2.02% -6.60% 65.72% -141.49% 14.36% 23.74% 25.96% -13.56% 21.19% -103.71%
EPS Q/Q Growth		 -11.59% -1.30% -6.41% 66.27% -142.86% 0.00% 0.00% 26.67% 36.36% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 16.49% -46.19% 54.71% 12.58% -46.83% -48.65% 61.69% -71.49% 63.13% -121.02% -63.22%
Free Cash Flow Firm Q/Q Growth		 8.30% 23.17% 107.85% 727.73% -64.62% 16.38% -112.95% 37.90% -465.53% 104.34% -13,282.33%
Invested Capital Q/Q Growth		 -27.22% 5.08% -82.77% 33.92% -180.39% 74.50% -716.07% 49.81% -194.90% 18.72% -0.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -186.81% -248.30% -184.11% -81.07% -170.52% -158.84% -122.55% -52.65% -81.28% -62.23% -147.10%
Operating Margin		 -186.87% -248.31% -184.11% -81.32% -169.41% -158.85% -122.80% -53.04% -81.30% -62.23% -147.09%
EBIT Margin		 -186.81% -248.30% -184.11% -81.07% -170.52% -158.84% -122.55% -52.65% -81.28% -62.23% -147.10%
Profit (Net Income) Margin		 -174.34% -233.96% -175.38% -71.09% -162.53% -152.23% -116.75% -49.66% -75.57% -56.56% -140.73%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.33% 94.22% 95.26% 87.69% 95.31% 95.84% 95.26% 94.31% 92.97% 90.89% 95.67%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -487.71% -494.59% -500.00% -218.70% -906.43% -706.05% 0.00% -6,714.54% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -485.06% -491.49% -496.25% -217.65% -902.66% -702.30% 0.00% -6,712.20% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 456.87% 452.27% 462.88% 201.71% 865.29% 660.90% 0.00% 6,692.89% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.84% -42.32% -37.12% -16.99% -41.13% -45.15% -51.83% -21.65% -40.00% -37.01% -47.04%
Cash Return on Invested Capital (CROIC)		 -502.58% -395.41% -384.93% -324.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -37.47% -52.54% -42.61% -20.45% -48.71% -54.03% -41.68% -22.96% -31.70% -28.98% -77.86%
Return on Assets (ROA)		 -34.97% -49.50% -40.59% -17.93% -46.42% -51.78% -39.70% -21.65% -29.47% -26.34% -74.49%
Return on Common Equity (ROCE)		 -30.83% -42.31% -37.11% -16.99% -41.12% -45.14% -51.82% -21.65% -39.99% -37.00% -47.03%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -51.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.88 -0.89 -0.94 -0.35 -0.77 -0.66 -0.51 -0.38 -0.44 -0.35 -0.68
NOPAT Margin		 -130.81% -173.82% -128.88% -56.92% -118.58% -111.20% -85.96% -37.13% -56.91% -43.56% -102.96%
Net Nonoperating Expense Percent (NNEP)		 -2.65% -3.10% -3.75% -1.05% -3.76% -3.75% -3.01% -2.35% -2.04% -1.68% -4.44%
Return On Investment Capital (ROIC_SIMPLE)		 -8.97% -10.23% -12.57% -4.97% -12.81% -12.88% -11.39% -9.64% -5.90% -5.06% -11.20%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 141.67% 163.45% 155.56% 121.41% 108.77% 110.68% 111.50% 79.38% 80.37% 80.26% 163.53%
R&D to Revenue		 145.19% 184.86% 128.55% 59.91% 160.64% 148.17% 111.30% 73.66% 100.93% 81.97% 83.56%
Operating Expenses to Revenue		 286.87% 348.31% 284.11% 181.32% 269.41% 258.85% 222.80% 153.04% 181.30% 162.23% 247.09%
Earnings before Interest and Taxes (EBIT)		 -1.26 -1.27 -1.34 -0.50 -1.11 -0.94 -0.72 -0.54 -0.62 -0.50 -0.97
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.26 -1.27 -1.34 -0.50 -1.11 -0.94 -0.72 -0.54 -0.62 -0.50 -0.97
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.54 0.67 0.84 0.95 1.02 0.79 1.36 1.22 0.67 0.88 1.10
Price to Tangible Book Value (P/TBV)		 0.54 0.67 0.84 0.95 1.02 0.79 1.36 1.22 0.67 0.88 1.10
Price to Revenue (P/Rev)		 2.09 2.38 2.49 2.64 2.46 1.56 2.47 1.69 1.67 1.92 2.04
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.52 0.25 0.00 0.00 0.06
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.94 -0.92 -0.93 -0.93 -0.96 -0.94 -1.02 -1.00 -1.05 -1.04 -1.07
Leverage Ratio		 1.08 1.07 1.13 1.12 1.11 1.10 1.21 1.19 1.14 1.13 1.17
Compound Leverage Factor		 1.01 1.01 1.07 0.98 1.06 1.05 1.15 1.13 1.06 1.03 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.02% 0.02% 0.02% 0.03% 0.03% 0.04% 0.04% 0.05% 0.02% 0.02% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.98% 99.98% 99.98% 99.97% 99.97% 99.96% 99.96% 99.95% 99.98% 99.98% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -20.73 -23.32 -27.32 -29.16 -35.05 -43.37 -46.96 -51.29 -29.25 -30.42 -34.97
Noncontrolling Interest Sharing Ratio		 0.02% 0.02% 0.02% 0.03% 0.02% 0.03% 0.03% 0.03% 0.02% 0.03% 0.02%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.84 11.69 5.05 6.96 7.37 8.20 5.93 4.56 8.32 7.93 7.43
Quick Ratio		 11.10 10.92 4.60 6.78 6.89 7.73 5.29 3.71 8.14 7.67 7.23
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.14 -0.88 0.07 0.57 0.20 0.23 -0.03 -0.02 -0.11 0.00 -0.61
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.20 0.21 0.23 0.25 0.29 0.34 0.34 0.44 0.39 0.47 0.53
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.81 0.85 0.15 0.20 -0.16 -0.04 -0.33 -0.17 -0.49 -0.40 -0.40
Invested Capital Turnover		 3.73 2.85 3.88 3.84 7.64 6.35 -26.82 180.84 -9.21 -14.60 -8.95
Increase / (Decrease) in Invested Capital		 0.26 -0.01 -1.01 -0.92 -0.97 -0.89 -0.48 -0.36 -0.33 -0.36 -0.07
Enterprise Value (EV)		 -3.67 -2.01 -1.03 -0.18 -0.01 -1.14 1.27 0.72 -2.91 -1.21 0.20
Market Capitalization		 5.32 5.81 6.27 6.66 6.15 4.02 6.05 4.84 4.97 6.14 6.67
Book Value per Share		 $6.36 $5.63 $4.83 $4.56 $3.89 $3.32 $2.88 $2.56 $3.23 $3.03 $2.65
Tangible Book Value per Share		 $6.36 $5.63 $4.83 $4.56 $3.89 $3.32 $2.88 $2.56 $3.23 $3.03 $2.65
Total Capital		 9.80 8.68 7.45 7.04 6.01 5.12 4.45 3.96 7.40 6.95 6.07
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -8.98 -7.82 -7.30 -6.84 -6.17 -5.16 -4.78 -4.12 -7.88 -7.35 -6.47
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.21 -0.16 -0.87 -0.82 -0.47 -0.35 -0.33 -0.17 -0.80 -0.71 -0.71
Debt-free Net Working Capital (DFNWC)		 8.78 7.66 6.43 6.02 5.69 4.81 4.45 3.96 7.08 6.64 5.76
Net Working Capital (NWC)		 8.78 7.66 6.43 6.02 5.69 4.81 4.45 3.96 7.08 6.64 5.76
Net Nonoperating Expense (NNE)		 0.29 0.31 0.34 0.09 0.29 0.24 0.18 0.13 0.14 0.10 0.25
Net Nonoperating Obligations (NNO)		 -8.98 -7.82 -7.30 -6.84 -6.17 -5.16 -4.78 -4.12 -7.88 -7.35 -6.47
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -8.10% -6.73% -34.57% -32.55% -18.89% -13.72% -13.47% -5.79% -26.94% -22.27% -21.86%
Debt-free Net Working Capital to Revenue		 345.56% 313.27% 255.02% 238.49% 227.70% 186.21% 181.92% 138.38% 237.93% 208.05% 176.62%
Net Working Capital to Revenue		 345.56% 313.27% 255.02% 238.49% 227.70% 186.21% 181.92% 138.38% 237.93% 208.05% 176.62%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.77) $0.00 $0.00 ($0.28) ($0.68) ($0.59) ($0.45) ($0.33) ($0.21) $0.00 ($0.41)
Adjusted Weighted Average Basic Shares Outstanding		 1.53M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.70M 2.29M 2.29M
Adjusted Diluted Earnings per Share		 ($0.77) $0.00 $0.00 ($0.28) ($0.68) ($0.59) ($0.45) ($0.33) ($0.21) $0.00 ($0.41)
Adjusted Weighted Average Diluted Shares Outstanding		 1.53M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.70M 2.29M 2.29M
Adjusted Basic & Diluted Earnings per Share		 ($0.77) $0.00 $0.00 $0.00 ($0.68) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 1.54M 2.29M 2.29M 2.29M 2.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.88 -0.89 -0.94 -0.35 -0.77 -0.66 -0.51 -0.38 -0.44 -0.35 -0.68
Normalized NOPAT Margin		 -130.81% -173.82% -128.88% -56.92% -118.58% -111.20% -85.96% -37.13% -56.91% -43.56% -102.96%
Pre Tax Income Margin		 -174.34% -233.96% -175.38% -71.09% -162.53% -152.23% -116.75% -49.66% -75.57% -56.56% -140.73%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Xenetic Biosciences (NASDAQ:XBIO) remains an early-stage biotechnology company with recurring operating losses and negative operating cash flow. The latest quarter showed revenue of $660,601, down from $806,923 in Q1 2026 but up from $589,897 in Q2 2025. Revenue has generally remained in the $500,000-to-$1.0 million range across the reported periods, without a clear sustained growth trend.

  • Revenue improved year over year in Q2 2026. Operating revenue rose approximately 12% from $589,897 in Q2 2025 to $660,601, while Q1 2026 revenue was up roughly 36% from Q1 2025.
  • Operating losses improved in the first quarter of 2026 compared with the prior-year quarter. The Q1 operating loss narrowed to $502,117 from $942,409 in Q1 2025, reflecting lower SG&A and research and development spending.
  • The balance sheet remains lightly leveraged. As of June 30, 2026, Xenetic had $6.47 million in cash and equivalents against $894,977 of current liabilities and no reported noncurrent debt.
  • Liquidity provides some operating flexibility. Based on Q2 operating cash usage of $875,489, the company held cash equivalent to approximately seven quarters of that quarter's operating burn, although actual runway will depend on future spending, revenue and financing activity.
  • Interest and investment income continues to provide a modest offset to operating losses. The company recorded $42,067 of interest and investment income in Q2 2026, compared with $45,756 in Q1.
  • Gross margin data should be interpreted cautiously. Reported cost of revenue was zero in the periods provided, causing revenue to equal gross profit. This may reflect the company's business model or accounting presentation, but it does not eliminate the substantial costs associated with operations and development.
  • XBIO has remained unprofitable throughout the reported period. Net losses were $929,695 in Q2 2026, $456,382 in Q1 2026, and $579,076 in Q4 2025. The Q2 2026 loss was also worse than the $688,703 loss reported in Q2 2025.
  • Operating expenses continue to exceed revenue by a wide margin. Q2 2026 SG&A and R&D expenses totaled $1.63 million, approximately 2.5 times quarterly revenue. R&D spending alone was $552,013, indicating continued investment but also ongoing pressure on earnings.
  • Operating cash flow remains consistently negative. Xenetic used $875,489 in operating cash during Q2 2026, following cash outflows of $536,377 in Q1 2026 and $242,682 in Q4 2025. The company has generated no positive operating cash flow in the reported quarters.
  • Cash reserves have declined materially over the longer period and financing has supported liquidity. Cash fell from $9.78 million in Q3 2023 to $6.47 million in Q2 2026. The $4.00 million financing inflow in Q4 2025 helped rebuild cash, highlighting the potential importance of future capital raises if operating losses continue.

Overall, Xenetic's low debt and remaining cash balance are supportive factors, but the company has not yet demonstrated sustainable profitability or positive operating cash flow. Investors should closely monitor revenue consistency, R&D efficiency, cash burn and any additional equity financing, particularly because weighted-average shares increased from approximately 1.54 million in 2025 to 2.29 million in Q2 2026, creating potential dilution for existing shareholders.

09/04/26 07:55 AM ETAI Generated. May Contain Errors.

Xenetic Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Xenetic Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Xenetic Biosciences' net income appears to be on a downward trend, with a most recent value of -$2.68 million in 2025, falling from -$12.51 million in 2015. The previous period was -$3.96 million in 2024. Check out Xenetic Biosciences' forecast to explore projected trends and price targets.

Xenetic Biosciences' total operating income in 2025 was -$2.83 million, based on the following breakdown:
  • Total Gross Profit: $2.98 million
  • Total Operating Expenses: $5.81 million

Over the last 10 years, Xenetic Biosciences' total revenue changed from $0.00 in 2015 to $2.98 million in 2025, a change of 297,641,100.0%.

Xenetic Biosciences' total liabilities were at $968.03 thousand at the end of 2025, a 8.2% increase from 2024, and a 90.6% decrease since 2015.

In the past 10 years, Xenetic Biosciences' cash and equivalents has ranged from $132.23 thousand in 2015 to $18.24 million in 2021, and is currently $7.88 million as of their latest financial filing in 2025.

Over the last 10 years, Xenetic Biosciences' book value per share changed from 0.04 in 2015 to 3.23 in 2025, a change of 7,251.9%.


Related Companies

Financial statements for NASDAQ:XBIO last updated on 9/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Inside the site of Elon’s next major breakthrough
Inside an ordinary Fremont, California building, Elon Musk is reportedly developing technology he says could e...
Monument Traders Alliance | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel